Fairvalue-Calculator Fairvalue-Calculator
EN DE

New Journey Health Technology Group (002219) Fair Value & Analysis

Healthcare · CN · Market cap 6.9B CNY

Price¥1.89
Fair Value¥0.7500
Upside-60.3%
Quality94/100
Evidence: High Range ¥0.4000 – ¥1.06

Analysis

New Journey Health Technology Group (002219) currently trades at ¥1.89, while our model-based Fair Value estimate is ¥0.7500 — implying the stock looks roughly 60.3% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

New Journey Health Technology Group Co.,LTD, together with its subsidiaries, provides medical services and pharmaceuticals products in China and internationally. The company operates regional medical centers to treat aging diseases, such as tumors, cardiovascular, cerebrovascular, and orthopedics. It is also involved in the research, development, production, and sale of medicines comprising Duyiwei capsules, Ginsengqi Schisandra tablets, Maiping tablets, Prosta Antong tablets, Gongzhongning capsules, Wuhu San, Wei Funing capsules, and other proprietary Chinese medicine products. In addition, it engages in Chinese herbal medicine planting; investment management; retail business; wholesale trading activities; and provision of resident services. The company was formerly known as Hengkang Medical Group Co.,Ltd. New Journey Health Technology Group Co.,LTD was founded in 2001 and is headquartered in Beijing, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.